Setting up in Europe · Part 1 of 3
Switzerland, Luxembourg or the UK? Where to Set Up a Pharma, Biotech or Industrial Company in Europe (2026)
Chinese and Korean drug developers now license a large share of the world’s new drug candidates to Western partners, and more of them want a company of their own in Europe. What Switzerland, Luxembourg and the United Kingdom each offer, where each falls short, and why the country of incorporation and the place of management are two separate decisions.
Setting up in Europe: a three-part series
- Part 1: Switzerland, Luxembourg or the UK? (this article)
- Part 2: How to set up a company in Switzerland, Luxembourg or the UK, step by step · 25 November
- Part 3: From China and Korea to Europe: approvals, export controls and banks · 2 December
Pharma, biotech, chemical and industrial companies from Asia that want to set up a company in Europe usually choose between Switzerland, Luxembourg and the United Kingdom. Switzerland suits companies whose value sits in research, patents and partnerships: the Basel and Zurich cluster, cantonal tax rates from 11.66 to 20.54 per cent and relief of up to 90 per cent on patent income. Luxembourg is the only one of the three inside the EU, so a Luxembourg company can hold EU marketing authorisations and the other roles EU law reserves for companies established in the EU. The UK offers English-law shares that venture investors know and registration within days. Where the company is incorporated and where its board meets are separate choices, and the second usually decides where it pays tax.
The question comes up more often, and increasingly from Asia. Chinese drug developers signed USD 135.7 billion of out-licensing agreements in 2025, one-third of global licensing spend (Cooley). Korean pharma and biotech companies had signed USD 8.5 billion of technology export deals by early June 2026, more than in the whole first half of 2025, the previous record (Asia Economy). BioCentury counted 14 new Western companies built around Asian assets in 2025 and at least 13 more in the first half of 2026. Each of them had to decide where to incorporate.
| At a glance (November 2026) | Switzerland | Luxembourg | United Kingdom |
|---|---|---|---|
| Usual company | AG: CHF 100,000 capital, half paid in | S.à r.l.: EUR 12,000 capital, payable within 12 months | Private limited company: no minimum capital |
| Time to register | Three to five weeks | Two to four weeks | Within days |
| Local requirement | One person with signing authority resident in Switzerland | Registered office in Luxembourg, often with a licensed domiciliation agent | UK registered office; directors and owners verify their identity |
| Inside the EU | No | Yes | No |
| Can hold an EU marketing authorisation | No | Yes | No |
| Corporate tax, 2026 | 11.66% (Lucerne) to 20.54% (Bern) | 23.87% in Luxembourg City | 25%; 19% on small profits |
| IP regime | Cantonal patent box, up to 90% relief | 80% of qualifying IP income exempt | Patent box at 10% |
| Withholding tax on dividends, before treaties | 35% | 15%; nil for qualifying parents in treaty countries | None |
| Free trade agreement with China | Yes, since 2014; upgrade signed October 2026 | No | No |
| Free trade agreement with Korea | Yes, through EFTA, since 2006 | Yes, through the EU, since 2011 | Yes; upgrade signed December 2025 |
| If the board meets in Switzerland | Swiss tax resident | Usually Swiss tax resident under the treaty; EU directive benefits fall away | Usually Swiss tax resident under the treaty; files in both countries |
| Suits | IP and licensing companies close to the Basel and Zurich pharma cluster | Companies that EU medicines or chemicals rules require to be established in the EU | Venture-backed biotech whose investors expect English-law shares |
Tax rows assume the company is tax resident in the country shown. Registration times are planning figures.
Why a European company at all
In our experience the first reason is rarely tax. It is who will sign. A licensing partner, a European fund or a European bank weighs the counterparty as carefully as the asset: the law that governs the contract, the courts behind it and the board that answers for the company. A company in Switzerland, Luxembourg or the UK, with directors the counterparty can meet, changes who will fund an asset and on what terms. The second reason is regulation. Selling a medicine or registering a chemical in Europe requires a company established in the right place, and the three countries differ sharply on that point.
Switzerland: the research and licensing base
Roche and Novartis are headquartered in Basel, ChemChina bought Basel-based Syngenta for USD 43 billion in 2017, and Swiss chemical and pharmaceutical exports reached CHF 152.1 billion in 2025, more than 52 per cent of all Swiss exports (scienceindustries). Asian companies use the cluster. Jiangsu Hengrui set up Hengrui Europe Therapeutics AG in Basel in 2020 for its European clinical development. BeOne Medicines, formerly BeiGene, moved its domicile from the Cayman Islands to Basel in May 2025. Windward Bio, a Basel company built on antibodies licensed from Chinese developers, has raised USD 365 million since January 2025. In July 2026 Samsung Biologics agreed to buy PolyPeptide Group of Baar for CHF 1.46 billion through a Swiss special-purpose company, the largest acquisition in the history of Korea’s pharma and biotech industry. And since May 2026 Basel Area Business & Innovation has run a programme with Roche Korea and two Korean public agencies that brings selected Korean biopharma companies into the Basel cluster.
Corporate tax is 11.66 per cent in Lucerne, 11.71 per cent in Zug, 19.47 per cent in Zurich and 20.54 per cent in Bern (KPMG, Swiss Tax Report 2026). Basel-Stadt charges 13.04 per cent, rising to 14.53 per cent on profits above CHF 50 million. Cantonal patent boxes relieve up to 90 per cent of qualifying patent income, and an additional deduction of up to 50 per cent applies to Swiss research costs (Switzerland Global Enterprise). Switzerland levies no withholding tax on royalties. It is the only one of the three countries with a free trade agreement with China, in force since 2014, and an upgrade was signed on 30 October 2026. Only a company with a registered office, address or branch in Switzerland can hold a Swiss marketing authorisation (Therapeutic Products Act, Art. 10).
The limit is the EU’s single market. Switzerland is not in the EU or the EEA, so a Swiss company cannot hold an EU marketing authorisation, and for medical devices Switzerland has been treated as a third country since May 2021.
Luxembourg: the EU company
Luxembourg’s decisive advantage for life sciences is membership of the EU. The holder of an EU marketing authorisation must be established in the EU or EEA (Directive 2001/83/EC; Regulation 726/2004), as must the sponsor of an EU orphan designation and the legal representative of a trial sponsor based outside the EU. Under REACH, chemicals made outside the EU are registered by an importer or by an only representative established in the EU. A Luxembourg company can take all of these roles. It can also hold a UK marketing authorisation, because the UK accepts holders established in the UK or in the EU and EEA (MHRA).
The combined corporate tax rate in Luxembourg City is 23.87 per cent in 2026, and the draft 2027 budget would cut it to 22.80 per cent (Loyens & Loeff). Under the IP regime, 80 per cent of net income from qualifying patents and software is exempt, an effective rate of 4.774 per cent in Luxembourg City (PwC). Luxembourg levies no withholding tax on arm’s-length interest or royalties, and dividends to a qualifying corporate parent in a treaty country are exempt.
Formation has become simpler. Since 2 June 2026, founders of an S.à r.l. can pay the EUR 12,000 minimum capital up to 12 months after incorporation (Baker McKenzie), so the company no longer has to wait for a bank account. Luxembourg is also familiar ground for Chinese groups: seven major Chinese banks run their EU hubs from there (Luxembourg for Finance). One point needs early attention. Luxembourg’s investment screening law requires prior notification when an investor from outside the EEA takes control of a Luxembourg entity carrying out critical activities, which include health and biotechnology, and newly formed companies are not excluded (CMS).
The United Kingdom: the venture company
The UK’s strength is its capital market for young companies. Investors in London, and many in the US, know English-law shares and UK company law, and a private limited company can be registered within days with no minimum capital. Since 18 November 2025 every new director and person with significant control must verify their identity with Companies House.
The main corporation tax rate is 25 per cent, with 19 per cent on small profits. Companies that elect into the patent box pay 10 per cent on profits from qualifying patents, and the merged R&D scheme pays a taxable credit of 20 per cent of qualifying research spending (HMRC; PwC). The UK levies no withholding tax on dividends. It signed an upgraded free trade agreement with Korea in December 2025 and concluded negotiations on a modernised agreement with Switzerland in July 2026.
The UK is outside the EU, so a UK company cannot hold an EU marketing authorisation, although a UK marketing authorisation can be held by a company established in the UK or in the EU and EEA. The National Security and Investment Act requires clearance before anyone acquires control of a company active in one of 17 sensitive sectors, including synthetic biology, and lets the government call in other deals, including acquisitions of intellectual property.
Incorporated in one country, managed in another
The country of incorporation decides the company law, the shares investors buy and the regulatory roles the company can hold. Where the board meets and takes its decisions usually decides where the company is resident for tax. A UK or Luxembourg company whose board meets and decides in Switzerland is usually resident in Switzerland under the tax treaty. It still files in its home country, and a Luxembourg company in that position loses the benefits of the EU tax directives. Tax counsel should settle this in the first week, before anything is signed, because it changes which treaties apply to dividends and royalties.
Which country for which purpose
| What the company will do | Usual first choice | Why |
|---|---|---|
| Hold the rights to an asset outside Asia and license it | Switzerland | Patent relief, no withholding tax on royalties, partners nearby |
| Raise venture capital from UK and US investors | The UK | English-law shares; some US investors still ask for Delaware |
| Hold EU marketing authorisations, orphan designations or REACH registrations | Luxembourg or another EU state | EU law requires a company established in the EU |
| Run European clinical development near large pharma companies | Switzerland | Basel and Zurich talent and partners |
| Work with Chinese banks in the EU | Luxembourg | EU hubs of seven Chinese banks |
Two of the three are often combined: a Swiss or UK company that holds the rights and signs with partners, and an EU company that takes the regulatory roles. The same board can run both.
Key takeaway
Choose the country of incorporation by what the company has to do, and the place of management by where it should be governed and taxed. Switzerland for IP, partners and the pharma cluster; Luxembourg for anything EU law requires to be in the EU; the UK for venture capital under English law.
What none of the three solves
- Substance. Tax residence and treaty benefits follow where the board meets and decides. A company without real management fails with banks, investors and tax authorities in all three countries.
- Banks. Banks in Switzerland, Luxembourg and London run long onboarding for new companies owned from Asia. Plan for weeks, not days.
- US rules on China. The US Treasury’s proposal of 22 October 2026 would extend US outbound investment rules to biotechnology, prohibiting or requiring notice of certain US investments in China-linked companies wherever they are incorporated (Covington). A European address does not change that. Korea is not a country of concern under these rules.
- Tariffs. Origin follows where goods are made, not where the seller is registered.
- Cost. Directors, audits and salaries in all three countries cost more than a holding company in Hong Kong or Singapore.
What it means for companies considering Europe
- Write down what the company is for. Holding rights, signing contracts, regulatory filings, raising capital and running operations point to different countries.
- Plan the EU company early if a European marketing authorisation, trial, orphan designation or REACH registration is on the horizon.
- Decide where the board will meet before choosing directors; it settles tax residence.
- Start the bank early. In Switzerland the bank account comes before registration for cash capital; in Luxembourg and the UK it can follow, but the company cannot operate without it.
- Coming from China or Korea, start at home. Outbound investment filings and technology export rules come first; Part 3 covers both.
Frequently asked questions about setting up a company in Europe
Which is better for a biotech company: Switzerland, Luxembourg or the UK?
It depends on what the company will do. Switzerland suits holding and licensing IP close to the Basel and Zurich pharma cluster. Luxembourg suits anything EU law requires to be in the EU, such as holding EU marketing authorisations. The UK suits companies raising venture capital under English law. Many companies combine two of the three.
Can a Swiss or UK company hold an EU marketing authorisation?
No. The holder of an EU marketing authorisation must be established in the EU or the EEA. A Luxembourg company can hold one. A UK marketing authorisation can be held by a company established in the UK or in the EU and EEA, so a Luxembourg company can hold both.
What is the corporate tax rate in Switzerland, Luxembourg and the UK in 2026?
In Switzerland it ranges from 11.66 per cent in Lucerne to 20.54 per cent in Bern (KPMG). In Luxembourg City the combined rate is 23.87 per cent, and 80 per cent of qualifying IP income is exempt. In the UK the main rate is 25 per cent, with a 10 per cent rate on qualifying patent profits.
Can a UK or Luxembourg company be managed from Switzerland?
Yes. A company can be incorporated in one country and have its board meet and decide in another. A UK or Luxembourg company managed from Switzerland is usually tax resident in Switzerland under the tax treaty and still files in its home country. Tax counsel should confirm the position before incorporation.
Why are Chinese and Korean pharma companies setting up in Europe?
To give Western partners and investors a credible counterparty, to hold the EU and UK regulatory roles that require a local company, and to build European teams near pharma clusters. BeOne Medicines moved its domicile to Basel in 2025, and Samsung Biologics agreed in 2026 to buy Switzerland’s PolyPeptide Group for CHF 1.46 billion.
Why this matters for clients working with Breslin
Breslin sets up companies for pharma, biotech, chemical and industrial businesses in Switzerland, the UK, Luxembourg or elsewhere in the EU, and runs them from Switzerland: the board meets and decides in Zurich, with a resident director, an independent board member from the client’s industry and part-time management. We run the bank application with two banks in parallel and, if wanted, a first financing and the first hires. The service is described on our NewCo and headquarters page; licensing and company building around university and corporate assets run through our partnering, licensing and spin-offs practice. Breslin was founded in 1996 as the life sciences private equity group within Dresdner Bank and Allianz, and was a co-founding partner of Memo Therapeutics, the ETH Zurich spin-off that Ipsen agreed in July 2026 to acquire for up to EUR 700 million.
Conclusion
There is no single best country for a European company. Switzerland gives a research-led company credibility, partners and low taxes on patents. Luxembourg gives it a place inside the EU’s regulatory system. The UK gives it shares that venture investors know. The right answer is usually the one, or two, that match what the company must do in its first three years, combined with a deliberate choice of where its board will meet. Part 2, on 25 November, sets out the steps to form a company in each country. Part 3, on 2 December, covers the approvals needed in China and Korea.
Sources: Cooley (17 March 2026); Asia Economy (4 June 2026); BioCentury (June 2026); scienceindustries (29 January 2026); Basel Area on Hengrui; BeOne Medicines (27 May 2025); Windward Bio (4 May 2026); Korea Times (20 July 2026) and Edaily (31 August 2026) on Samsung Biologics; Basel Area Business & Innovation (May 2026); KPMG, Swiss Tax Report 2026 (19 May 2026); Switzerland Global Enterprise; Federal Council on the China FTA upgrade (20 August 2026); Xinhua (31 October 2026); Korea JoongAng Daily on the EFTA and Korea FTA; EEAS on the EU and Korea FTA; PwC, Luxembourg corporate tax, IP regime and withholding taxes; Loyens & Loeff on the 2027 budget; Baker McKenzie (May 2026); Luxembourg for Finance; CMS on Luxembourg FDI screening; MHRA on MAH location; Companies House; HMRC on the patent box; PwC, UK incentives and withholding taxes; MLex on the UK and Korea FTA (16 December 2025); Federal Council on the Switzerland and UK FTA (13 July 2026); UK government on the NSI Act; Covington (October 2026). Registration times are Breslin’s planning figures. Companies named are examples from public sources and are not Breslin clients. This article is informational and is not legal, tax or regulatory advice. It does not constitute an offer, a solicitation, a recommendation or investment advice; it is not directed at retail or non-professional investors. Breslin may act for holders or prospective buyers of securities of companies mentioned.
Further reading
Considering a company in Switzerland, Luxembourg or the UK?
A first conversation is confidential, carries no obligation and is answered by a partner.
